A MULTICENTER clinical trial will soon begin recruiting patients to see if ventricular assist devices (VADs) are an effective long-term treatment for patients with advanced congestive heart failure (CHF).
Although these implantable heart assist pumps are being used as a short-term "bridge to transplantation"—keeping patients with end-stage heart disease alive until a donor organ can be obtained—they have not been approved for long-term therapy.
The randomized, nonblinded, controlled trial, called REMATCH (for Randomized Evaluation of Mechanical Assistance and Treatment of Congestive Heart Failure), will seek to determine whether VADs and medical treatment are clearly superior to optimum medical treatment alone in improving patient survival and quality of life, said Eric A. Rose, MD, Valentine Mott/Johnson & Johnson Professor of Surgery and chair of the Department of Surgery at Columbia University's College of Physicians and Surgeons, in New York, NY.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 3
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Users' Guides to the Medical Literature
How Should We Treat Patients With Heart Failure? A Problem in Interpreting Study Results
Figure 17.1-1. Distribution of Brain Natriuretic Peptide Values Among Patients With and Without...
All results at
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.